What OpenAI’s superalignment team has been up to

The firm wants to prevent a superintelligence from going rogue.

Week in Review Sunday, December 24, 2023 This week's roundup: Now we know what OpenAI's superalignment team has been up to. Vertex sickle cell pill treatment. Google DeepMind used a large language model to solve an unsolved math problem. And more. Plus, subscribe today to save 25% and ensure you receive a print copy of the upcoming 10 Breakthrough Technologies 2024 list.   Now we know what OpenAI's superalignment team has been up to by Will Douglas Heaven The firm wants to prevent a superintelligence from going rogue. This is the first step. Read more → Vertex developed a CRISPR cure. It's already on the hunt for something better. by Antonio Regalado Thanks for the cure, CRISPR. Now companies want a pill to treat sickle-cell disease instead. Read more → Google DeepMind used a large language model to solve an unsolved math problem by Will Douglas Heaven They had to throw away most of what it produced but there was gold among the garbage. Read more → These six questions will dictate the future of generative AI by Will Douglas Heaven Generative AI took the world by storm in 2023. Its future—and ours—will be shaped by what we do next. Read more → Eric Schmidt has a 6-point plan for fighting election misinformation by Eric Schmidt The former Google CEO hopes that companies, Congress, and regulators will take his advice on board—before it's too late. Read more → Catch up on the stories readers are talking about: Here's a sneak peek at what made our 2024 list of 10 Breakthrough Technologies What are the hardest problems in tech we should be more focused on as a society?   A chip design that changes everything   10 Breakthrough Technologies 2022   Vertex will pay tens of millions to license a controversial CRISPR patent Subscribe & save 25% to get a print copy of our highly coveted 10 Breakthrough Technologies list, releasing January 2024. This annual issue highlights exceptional technological advancements and why they matter. SUBSCRIBE & SAVE 25% View in browser | This email was sent to manojdole1.InformationTech@blogger.com. Manage your preferences | Unsubscribe | Terms of Service | Privacy Policy MIT Technology Review · 196 Broadway, 3rd fl, · Cambridge, MA 02139 · USA Copyright © 2023 MIT Technology Review, All rights reserved. Opt out of all promotional emails and newsletters from MIT Technology Review